Completed PHASE3 INTERVENTIONAL NCT00437554

Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)

A 16-Week Controlled, Double Blind, Double Dummy, Randomized, Two Arm Parallel-Group Study to Compare the Efficacy and Safety of Amaryl M 1/250 mg b.i.d vs. Amaryl M SR 2/500 mg od. in Patients With Type 2 Diabetes Mellitus

Sponsor: Handok Inc.

Conditions Diabetes Mellitus, Type 2

Interventions Glimepiride

Updated 7 times since 2017 Last updated: Nov 28, 2007 Started: Aug 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Handok Inc. and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Handok Inc.

Data source: Handok Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea